BLX 0631
/ Biolexis Therap
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 01, 2024
Biolexis Therapeutics to Present Late-Breaking Poster at the American Association of Immunologists (AAI) Annual Meeting 2024
(PRNewswire)
- "Biolexis Therapeutics...today announced it will present a late-breaking poster at the 2024 American Association of Immunologists (AAI), taking place May 3-7, 2024, in Chicago, IL....Biolexis' scientific team will be presenting pre-clinical data demonstrating the efficacy of the company's novel PIM1-inhibitor, BLX-0631."
Late-breaking abstract • Preclinical • Systemic Lupus Erythematosus
April 21, 2024
Development of highly selective, potent, orally available PIM1 inhibitor BLX-0631 shows a therapeutics potential in Systemic Lupus Erythematosus (SLE) models
(IMMUNOLOGY 2024)
- "Ex vivo SLE patient samples and NZBWF1/J mouse model data support our selection of BLX-0631 as a candidate for IND-enabling studies."
Late-breaking abstract • Immunology • Inflammatory Arthritis • Lupus • Oncology • Systemic Lupus Erythematosus • IL1B • PIM1 • TNFA
March 06, 2024
Development of highly selective, potent, orally available PIM1 inhibitor BLX0631 shows a therapeutics potential in multiple myeloma models
(AACR 2024)
- "The present study demonstrates that PIM1 plays a vital role in the proliferation and survival of Multiple Myeloma. BLX-0631 induces full inhibition of all MM cell lines, suppresses cancer cell proliferation in vitro, and exhibits promising efficacy in MM tumor models. BLX-0631, a nominated IND candidate can serve as a novel targeted agent for treating Multiple Myeloma patients."
Hematological Malignancies • Multiple Myeloma • Oncology
April 01, 2024
Biolexis Therapeutics to Present Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
(PRNewswire)
- "Biolexis Therapeutics, Inc...today announced it will present five posters at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA."
Preclinical • Genito-urinary Cancer • Hematological Malignancies • Multiple Myeloma • Oncology • Prostate Cancer • Solid Tumor
1 to 4
Of
4
Go to page
1